

Sir:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
MARK W. PERLIN)	
Serial No. 09/849,809)	
Filed: May 4, 2001) METHOD AND SYSTEM FOR) NUCLEIC ACID SEQUENCING	
Art Unit: 1645)	-
Patent Examiner:)	
)	
	Pittsburgh, Pennsylvania 15213	
	August 6, 2001	CHETHICATE OF MAILING
Assistant Commissioner for Patents Washington, D.C., 20231	rugust o, 2007	11. Ally essibly that the correspondence is the presided with the United States from a first class shall in an exception of the Commissioner of Patents and the Commissioner of the Co

LETTER

Ansel M. Schwartz Registration No. 30,587

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated July 16, 2001, please enter the following remarks to the above-identified application.

REMARKS

The Initial Patent Examination Center states that the application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences as set forth in 37 CFR 1.821(a)(1) and (a)(2).

Applicant notes that 37 CFR 1.821(b) states that: "(b) Patent applications which contain disclosures of nucleotide and/or amino acid sequences, in accordance with the definition in paragraph (a) of this section, shall, with regard to the manner in which the nucleotide and/or amino acid sequences are presented and described, conform exclusively to the requirements of Sections 1.821 through 1.825."

Applicant respectfully submits that the application does not disclose or make claim to any specific or novel nucleotide sequences. The application describes generic techniques to determine DNA sequence information, such as DNA molecule length or nucleotide composition. These general references are made in order to enable the practice of a novel method that is broadly applicable to DNA. No claim is made to any particular nucleotide sequence, and any such specific sequence mentioned would be used solely for illustrative purposes and would not represent a novel sequence disclosure. Therefore, since the application does not contain any material "disclosure of nucleotide sequences", applicant

respectfully submits that CFR 1.821 through 1.825 are not applicable to any disclosed sequences in the application.

CEMINICATE OF MAILING

Lay certify that the correspondence is the actual color with the United States Posted that to as first class mail in an envelope at the Commissioner of Patents and the Lards, Washington C 2023

Ansel M. Schwartz

Registration No. 30,587

Respectfully submitted,

MARK W. PERLIN

Ansel M. Schwartz, Esquire

Reg. No. 30,587

One Sterling Plaza 201 N. Craig Street

Suite 304

Pittsburgh, PA 15213

(412) 621-9222

Attorney for Applicant